Emerging treatments
SHIP1 activators
SHIP1 protein is involved in cell signalling for a variety of processes and modulates immunity. A phase 2 study of an oral SHIP1 activator, AQX-1125, showed an overall average improvement of 2.4 in pain score from baseline at 6 weeks.[75] However, a larger phase 3 trial showed no difference from placebo after 12 weeks of treatment.[76]
Use of this content is subject to our disclaimer